Home Genelux announces promising data from two phase I trials of GL-ONC1...
 

Keywords :   


Genelux announces promising data from two phase I trials of GL-ONC1...

2015-05-28 22:50:38| Logistics - Topix.net

Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials evaluating its lead oncolytic virotherapy GL-ONC1 in head and neck cancer and malignant pleural mesothelioma demonstrate a favorable safety profile and support further investigation of the therapy in both indications. The results will be presented by lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center at the upcoming 2015 American Society of Clinical Oncology Annual Meeting, being held May 29-June 2 in Chicago, IL.

Tags: of data phase trials

Category:Transportation and Logistics

Latest from this category

All news

01.11Atlantic Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
31.10Atlantic Tropical Weather Outlook
31.10Eastern North Pacific Tropical Weather Outlook
31.10Atlantic Tropical Weather Outlook
31.10Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
01.11Atlantic Tropical Weather Outlook
01.11Eastern North Pacific Tropical Weather Outlook
01.11Boeing makes 38% pay rise offer in bid to end strike
01.11The house paints that promise much more than colour
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11Technology adoption: What's on the ag tech horizon for 2025
01.11Technology adoption: What's on the ag tech horizon for 2025
More »